CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference
CERo Therapeutics Holdings, Inc. announced that it will present preclinical data for its lead compound, CER-1236, targeting ovarian cancer during the Spring Scientific meeting of the Society for Immunotherapy of Cancer in San Diego on March 13, 2025.
The poster presentation, titled “TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” will highlight the potential of CER-1236 in treating various cancer types, including upcoming clinical trials in acute myeloid leukemia (AML) and ovarian cancer.
CEO Chris Ehrlich emphasized the company's commitment to sharing these findings and continuing the development of its innovative immunotherapy approach, which integrates features of both innate and adaptive immunity to enhance cancer treatment. The data will be made available on CERo's website at the time of the presentation.
The data presentation demonstrates the potential of CER-1236 across multiple cancer types, including ovarian cancer and non-small cell lung cancer, indicating broad applicability of the therapeutic.
The upcoming Phase 1 trial for CER-1236, with planned studies in various cancers, suggests strong future growth possibilities for the company.
The opportunity to share findings with the scientific community fosters collaboration and credibility in the immunotherapy field.
Confusion may arise from the company's focus on multiple cancer types without clear prioritization, potentially diluting stakeholder confidence in its lead compound, CER-1236.
CER-1236 is CERo's lead compound targeting ovarian cancer, showcasing preclinical results at the SITC conference. Where can I find the CER-1236 poster presentation? The poster will be available on CERo's website starting at 9:00 AM ET on March 13, 2025.
CERo is developing engineered T cell therapeutics, focusing on both hematological malignancies and solid tumors, including ovarian cancer.
